Highlights
- Glucuronate (GlucA) levels were reported to be significantly higher in serum of patients with schizophrenia. The accumulation of GlucA is known to be related to treatment-resistant (TR) schizophrenia, since GlucA is known to promote drug excretion by forming conjugates with drugs.
- Aldo-keto reductase family one member A1 (AKR1A1) is an oxidoreductase that catalyzes the reduction of GlucA. We identified 28 variants of the AKR1A1.
- Among them, we found that c.753G > A variant induces exon skipping, leading to a loss of gene expression and enzymatic activity. AKR1A1 mRNA expression in the whole blood cells of individuals with the c.753G > A variant tended to be lower than that in those without the variants, leading to lower AKR activity.
- Elevated GlucA may contribute to the pathophysiology of TR phenotype for these patients due to diminished enzymatic activity of AKR1A1 caused by mutation at c.753G > A.
Introduction
The accumulation of GlucA might be related to drug-resistant schizophrenia, since GlucA is known to promote drug excretion by forming conjugates with drugs. However, little is known about the molecular mechanisms underlying GlucA accumulation in patients with schizophrenia.
AKR1A1 is an approximately 40 kDa monomeric oxidoreductase, which is known to catalyze the reduction of GlucA. It can be assumed that AKR1A1 dysfunction leads accumulation of GlucA. Here, we aimed to explore genetic defects in AKR1A1 in patients with schizophrenia and identify the molecular mechanisms that cause the accumulation of GlucA.
Results
The AKR1A1 sequence was analyzed in patients with schizophrenia and control subjects, and 28 variants containing 4 novel variants were identified (Fig.1). Among them, four variants were found in the coding region. In particular, the c.753G>A variant was identified in 14 cases in the schizophrenia patient group and 5 subjects in the healthy group, and the c.264delC variant was observed in only one patient with schizophrenia.
Journal
Frontiers in Genetics
Article Title
AKR1A1 Variant Associated With Schizophrenia Causes Exon Skipping, Leading to Loss of Enzymatic Activity
Article Publication Date
6-Dec-2021